I am not a gambler, never have been and never will

I am not a gambler, never have been and never will be, but I have put way, way too much into IPIX in the eyes of most people and have been called a fool by more than a few.

But to me, there is quite a difference between blind luck and solid DD so I still sleep well at night though we are getting very, very close to the realization as to whether we are visionaries or misguided dreamers.

My only negative comment in regards to the company is that we should have never been put in the position we are today in regards to needing so badly a finalized OM/IBD deal and needing it within a matter of a handful of weeks. I know we can go on longer should one not develop, but at this stage of the game we could sure use some solid foundation in regards to our belief in mgt getting things done in a timely manner. For a myriad of reasons this year that has not been the case, though I am not blaming mgt for most of the delays. This alone pretty well sums up my only worry about IPIX and it is not that it will fail, but that it could lead to heavy dilution and that BP knows they have the upper hand in dealing with us. But even that is questionable, because we don't know how many BPs were/are/may again bid on the OM/IBD indications should the current term sheet fail to come to fruition. Maybe it failing in the overall scheme of things may be helpful to shareholders if a new bid is significantly higher. But at this time, we have only faith on which to fall back. To be honest, my fear is not that I won't make over a million dollars on this investment, just that I have always thought it was worth many tens of millions. In my heart I still do.

The strength is the pipeline. Enough can't be said about it and I firmly believe Brilacidin will develop into the lead drug for a new family of medicine and be the basis for many, many indications across a wide swath of conditions. I do believe it will be a Humira-type drug in terms of many uses and huge revenues, but unlike Humira it will do it with very, very few or no serious side effects. Prurisol IMO is as solid as a rock and will have excellent P2b results as the trial design was formulated to highlight the strengths of the drug against severe psoriasis and I also believe the additional workings against the IL17 and IL20 and other like pathways will prove highly useful in controlling many autoimmune and dermatology related conditions. Kevetrin keeps getting relegated to the back burner but with a pill now on the horizon I see it finally showing its strength by being able to be dosed many times a day (if that is needed, maybe just a few times a day will work) and the world of cancer will be set on its ear. I envision a time, next year in fact, when it starts having many complementary trials run with other cancer treatments and will prove highly successful. I have always thought Dr. M would win the Nobel Prize for Kevetrin and I still do.

Not too bad to only have to wait another week or two to finally have a better handle on when/if things are going to take place. I take the silence from mgt as highly favorable, the recent MFO financing as highly favorable, and only the delay in getting the P2b results released resulting in me scratching my head as to the delay at this point in time. Hope that gets cleared up by the end of the month.

It has been a long 2018, but I still believe we will head into 2019 with big smiles on the faces of all longs.